

Rates & Media

2020

Indexed through the National Library
of Medicine (PubMed/MEDLINE),
PubMed Central (PMC), and EMBASE

Co-Editors-in-Chief

Richard R. Furman, MD

Daniel J. George, MD

Section Editors

Sanjiv S. Agarwala, MD

Robert L. Coleman, MD

Andrew J. Armstrong, MD

Axel Grothey, MD

Craig M. Kessler, MD

Susan O'Brien, MD

Mark J. Ratain, MD

Hope S. Rugo, MD

Mark A. Socinski, MD

2019
RATE FREEZE
FOR 2020

Millennium Medical Publishing, Inc.

611 Broadway, Suite 310

New York, NY 10012

Phone: 212.995.5552

Fax: 212.995.5572

hematologyandoncology.net



EDITORIAL ADVISORY BOARD

Editors-in-Chief

Richard R. Furman, MD
Weill Cornell Medicine
New York Presbyterian
Hospital

Daniel J. George, MD
Duke University Medical Center

Section Editors

Melanoma in Focus

Sanjiv S. Agarwala, MD
St Luke's Cancer Center and
Temple University

Prostate Cancer in Focus

Andrew J. Armstrong, MD
Duke University Medical Center

Ovarian Cancer in Focus

Robert L. Coleman, MD
The University of Texas
MD Anderson Cancer Center

Colorectal Cancer in Focus

Axel Grothey, MD
West Cancer Center
University of Tennessee

Hematology

Craig M. Kessler, MD
Georgetown University
Medical School
Lombardi Comprehensive
Cancer Center

Hematologic Malignancies

Susan O'Brien, MD
University of California, Irvine

Drug Development

Mark J. Ratain, MD
The University of Chicago

Breast Cancer in Focus

Hope S. Rugo, MD
UCSF Helen Diller Family
Comprehensive Cancer Center

Lung Cancer in Focus

Mark A. Socinski, MD
Florida Hospital

Founding Editor

Bruce D. Cheson, MD
Georgetown University Hospital
Lombardi Comprehensive
Cancer Center

aHUS, TTP

Jeffrey C. Laurence, MD
Weill Cornell Medicine
New York Presbyterian
Hospital

BREAST CANCER

Howard A. Burris III, MD
The Sarah Cannon
Cancer Center

William Gradishar, MD
Northwestern University

Kathy D. Miller, MD
Indiana University
School of Medicine

Ruth O'Regan, MD
University of Wisconsin
Carbone Cancer Center

Lee Schwartzberg, MD
The West Clinic

George W. Sledge Jr, MD
Stanford University

COLORECTAL CANCER

Edward Chu, MD
UPMC Hillman Cancer Center
University of Pittsburgh

John L. Marshall, MD
Georgetown University Hospital

Mohamed E. Salem, MD
Carolinas Medical Center

Leonard Saltz, MD
Memorial Sloan Kettering
Cancer Center

ENDOCRINE CANCER

Alexandria Phan, MD
UT Health North Campus Tyler
MD Anderson Cancer Center

HEAD AND NECK CANCER

Marshall R. Posner, MD
Mount Sinai Medical Center

KIDNEY CANCER

Robert A. Figlin, MD
Cedars-Sinai Comprehensive
Cancer Center

Brian I. Rini, MD
Cleveland Clinic Taussig
Cancer Institute

LEUKEMIA

Jan A. Burger, MD, PhD
The University of Texas
MD Anderson Cancer Center

Elihu H. Estey, MD
Fred Hutchinson Cancer Center

Elias Jabbour, MD
The University of Texas
MD Anderson Cancer Center

Hagop M. Kantarjian, MD
The University of Texas
MD Anderson Cancer Center

Neil E. Kay, MD
Mayo Clinic, Rochester

LUNG CANCER

Jeffrey Crawford, MD
Duke University Medical Center

David S. Ettinger, MD
The Sidney Kimmel
Comprehensive Cancer Center
at Johns Hopkins

Richard J. Gralla, MD
Albert Einstein College of Medicine

Roy S. Herbst, MD, PhD
Yale Cancer Center

David H. Johnson, MD
University of Texas
Southwestern Medical Center

Corey J. Langer, MD, FACP
University of Pennsylvania
Hematology-Oncology Division

LYMPHOMA

George P. Canellos, MD
Dana-Farber Cancer Institute
Harvard Medical School

Andre Goy, MD
Hackensack University
Medical Center

Steven M. Horwitz, MD
Memorial Sloan Kettering
Cancer Center

Brad S. Kahl, MD
Washington University
School of Medicine

John P. Leonard, MD
Weill Cornell Medicine
New York Presbyterian Hospital

Craig H. Moskowitz, MD
University of Miami
Sylvester Comprehensive Cancer
Center

MELANOMA

John M. Kirkwood, MD
University of Pittsburgh
Cancer Institute

MULTIPLE MYELOMA

Kenneth C. Anderson, MD
Dana-Farber Cancer
Institute

James R. Berenson, MD
Institute for Myeloma
& Bone Cancer Research

Sundar Jagannath, MD
Mount Sinai Medical Center

Paul G. Richardson, MD
Harvard Medical School
Dana-Farber Cancer
Institute

MYELOPROLIFERATIVE NEOPLASMS

Claire Harrison, MD, FRCP
Guy's and St Thomas' Hospital

John O. Mascarenhas, MD
Mount Sinai Medical Center

Ruben A. Mesa, MD
UT Health San Antonio
Cancer Center

Srdan Verstovsek, MD, PhD
The University of Texas
MD Anderson Cancer Center

NEUTROPENIA

David C. Dale, MD
University of Washington

OVARIAN CANCER

Maurie Markman, MD
Cancer Treatment Centers
of America

PANCREATIC CANCER

Margaret Tempero, MD
University of California,
San Francisco Comprehensive
Cancer Center

PEDIATRIC HEM/ONC

Mitchell S. Cairo, MD
New York Medical College

PROSTATE CANCER

David B. Agus, MD
University of Southern California
Keck School of Medicine

Michael A. Carducci, MD
The Sidney Kimmel
Comprehensive Cancer Center
at Johns Hopkins

SARCOMAS/GISTS

George D. Demetri, MD
Dana-Farber Cancer Institute
Harvard Medical School

Clinical Advances in
HEMATOLOGY & ONCOLOGYTM
A Peer-Reviewed Journal

CEO and Copublisher

Steven H. Kurlander

President and Copublisher

Paul H. McDaniel

Editorial Director

Devon Schuyler

Contributing Editor

Jacquelyn Matos

Art Director

Vanessa Ray

Indexed in PubMed/MEDLINE and EMBASE

ISSN: 1543-0790

Mission

The mission of *Clinical Advances in Hematology & Oncology* (CAH&O) is to contribute to the advancement of these inter-related fields by providing indispensable editorial content to oncologists, hematologist/oncologists, and pure hematologists. CAH&O fulfills the voiced need of practicing physicians for a practical and readable journal containing the most up-to-date clinical information in malignant and nonmalignant hematologic disorders, as well as solid tumor cancers. CAH&O is also dedicated to being the leader in editorial coverage of targeted therapy.

CAH&O's main editorial departments are:

- Thought leader-driven review articles
- Advances columns featuring engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development
- Counterpoints: Section addressing clinical controversies in hematology/oncology

Editorial Direction

A peer-reviewed monthly journal, CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of experts in the field. CAH&O contains several monthly columns providing cutting edge content on current issues in these fast-moving fields, including:

- In Focus: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, or Melanoma
- Pro/Con: Experts present their views on controversial issues in hematology and oncology
- Clinical Trials Broadcast: Summaries of ongoing, phase III clinical trials in vital therapeutic areas
- Hem/Onc News: Briefs about the latest developments and global meeting coverage
- Clinical Updates: Peer-reviewed updates on landmark therapeutic developments

Circulation

Clinical Advances in Hematology & Oncology circulates to over 24,000 hematology & oncology physicians.

Specialty	Circulation
Colon/Rectal Surgery	1,821
Gynecology/Oncology	672
Hematology	1,446
Hematology/Oncology	9,152
Musculo-Skeletal Oncology	120
Medical Oncology	3,964
Pediatric Hematology/Oncology	2,646
Radiation Oncology	2,500
Surgical Oncology	465
Urology	1,700
Total Circulation	24,486
<i>(As of August 2019)</i>	



2020 Print Advertising Rates

Effective Date: January 2020

Agency Commission: 15% of gross on space, color, and position if paid within 30 days.

Earned Rate: Frequency Discounts are earned on the basis of accumulated ad space placed within a 12-month period. All pages of a parent company and its subsidiaries placed in *Clinical Advances in Hematology & Oncology* are combined to determine the earned rate for the publication.

B&W Page Rates	Full Page	2/3 Page	1/2 Page	1/3 Page	1/4 Page
1x	\$4,265	\$3,635	\$2,875	\$2,255	\$1,665
6x	\$4,215	\$3,575	\$2,815	\$2,190	\$1,595
12x	\$4,140	\$3,505	\$2,755	\$2,135	\$1,545
24x	\$4,065	\$3,445	\$2,705	\$2,070	\$1,470
36x	\$4,005	\$3,355	\$2,630	\$2,010	\$1,410
48x	\$3,950	\$3,320	\$2,575	\$1,950	\$1,345
60x	\$3,915	\$3,285	\$2,535	\$1,910	\$1,315
72x	\$3,880	\$3,255	\$2,505	\$1,875	\$1,290
84x	\$3,850	\$3,230	\$2,475	\$1,845	\$1,255
96x	\$3,815	\$3,200	\$2,450	\$1,785	\$1,225
108x	\$3,790	\$3,165	\$2,415	\$1,755	\$1,200
120x	\$3,755	\$3,125	\$2,380	\$1,730	\$1,160

Color Rates *	6-Color	5-Color	4-Color	3-Color	2-Color	Matched PMS	Metallic
	\$2,860	\$2,550	\$2,075	\$1,975	\$935	\$990	\$1,300

* In addition to earned B/W rates; apply to each full or fractional page. No bleed charge.

Inserts	2-page (2x b/w page rate), 4-page (4x b/w page rate), 6-page (6x b/w page rate), 8-page (8x b/w page rate) plus \$800 net insert charge.
BRC's	\$1,665
Cover Tips (supplied)	\$22,500 net (Price based on single-leaf, 2-sided tips supplied by advertiser to our printer.)

Covers and Premium Rates	Position	B/W Rate Plus
	Cover 4 (2-page minimum)	50%
	Cover 2 (2-page minimum)	25%
	Page opposite 1st Table Contents	20%
	Page opposite 2nd Table of Contents	15%
	Page opposite first editorial page	15%

Continuity Discount Program: Advertise your product in all 12 issues in 2020, and receive a 5% discount on each insertion as placed. Advertise your product in 9 issues in 2020, and receive a 3% discount on each insertion as placed.

Cover Tips

The cost to run a supplied Cover Tip, standard size 2-page (single leaf, front and back), to the full circulation of *CAH&O* is \$22,500 net. Please see the next page for production specifications. *CAH&O* can accommodate variations in size and dimension and will be quoted on an individual basis from provided samples.

Bonus Distribution: The most recent issues of *Clinical Advances in Hematology & Oncology* will be made available to all attendees at the following major oncology meetings:

- American Society of Clinical Oncology (May Issue)
- Chemotherapy Foundation Symposium (October Issue)
- American Society of Hematology (November Issue)
- San Antonio Breast Cancer Symposium (December Issue)

2020 Closing Dates

Issuance: Monthly.

Commitment of Space: 1st of the preceding month (ie, January 1st for the February issue).

Material Due Date: 15th of the preceding month (ie, January 15th for the February issue).

Insert Due Date: 20th of the preceding month (ie, January 20th for the February issue).

Ad Sizing (run-a-book ads)

Ad Unit	Trim Size	Bleed	Live Area
2-Page Spread	16 1/4 " (width) x 10 7/8" (height)	16 1/2" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
Full Page	8 1/8 " (width) x 10 7/8" (height)	8 3/8" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
Half Page Horizontal	8 1/8" (width) x 5.0" (height)	Ad can bleed on top and sides only. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim
Half Page Vertical	4.0" (width) x 10 7/8" (height)	Ad can bleed on top, bottom, and either into gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/4 inch for binding.
Quarter Page	4.0" (width) x 5.0" (height)	Ad can bleed on top and gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/4 inch for binding.

Paper Stock

Paper Stock	Body Pages: 45# coated. Covers: 80# coated.
-------------	---

Specifications for Electronic Files

Disks	Macintosh-formatted CD.
File Format	Press ready, high res PDF only. (All files and fonts must be embedded; do not save PDF with unlinked OPI data)
	PDF needs to include crop marks and bleed. Make sure PDF is not set to crop document to frame edges.

Images/Color/Resolution

4 Color Scans	Resolution should be 2× the screen ruling (and at least 300 dpi). Color should be CMYK.
Proofs	Please provide one set of progressive/chromalin proofs for all color pages. Provide a laser print of all black and white pages. All printouts should indicate trims, bleeds, folds, color breaks, etc. Disks and proofs should be mailed to the publisher. Label disks with file and company name. Provide graphics contact information.

Specifications for Printed Inserts **Insert quantity** (includes spoilage allowance): 32,000.

Sizes	2-, 4-, 6-, or 8-page folded supplied inserts. Maximum 8 3/8" and specification.
Insert Trimming	- The final trim size needs to be 8 3/8" x 11 1/8" - Inserts jog to foot. This means that our printer will trim an additional 1/8" from the top. Keep this in mind in your design. - Live area: The type should be at least 3/8" from gutter grind, 3/8" from head and 1/4" from face and 1/4" from the foot.
Shipping	Preprinted inserts should be shipped directly to the printer at the address below. Please note the journal name and issue date on your shipment. For contracts or insertion orders, please contact the publisher.

Cover Tip Specifications:

Trim Size: 7.75" (width) x 4.0" (height). Extend bleed out 1/8" beyond trim. Paper weight: Use 70 lb. or 80 lb.

Publisher

Steve Kurlander or Paul McDaniel
Millennium Medical Publishing, Inc.
611 Broadway, Suite 310
New York, NY 10012
Tel: 212-995-2211; Fax: 212-995-5572
e-mail: shk@clinicaladvances.com
phm@clinicaladvances.com

Printer

LSC Communications
13487 South Preston Highway
Lebanon Junction, KY 40150
Attn: Kevin Baugh, H&O, Issue Date

*Please indicate counts on the packing slip and on each of the cartons

Please send a sample of all shipped inserts to the publisher at the address provided at left.

Website Banner Ads

2019 Average Stats*


- Average visit duration = 1 minute, 19 seconds
- Average monthly unique visitors = 28,878
- Average monthly visits = 36,420
- Average monthly page views = 43,273
- Average monthly impressions = 74,366
- 18,591 per 25% share of voice (SOV)
- CTR = 0.12%

*Based on average stats Jan-Jun 2019, Google Analytics, WordPress, US only

Hematologyandoncology.net is the online home of the monthly journal, *CAH&O—Clinical Advances in Hematology & Oncology*. Access to the Web site is free for recipients of the print edition of *CAH&O*. Hematologyandoncology.net complements the journal's goal to improve the quality of cancer care by addressing oncology practice for all disease stages and presentations.

Ad Sizes Available

- Leaderboard (728 x 90)
- Medium Rectangle (300 x 250)



Clinical Advances in Hematology & Oncology e-TOCs

e-TOC Average Stats

Average open rate of *CAH&O* e-TOC

- Total distribution: over 17,000 hematology and oncology clinicians and professionals
- Average open rate: 13.8%
- Click-to-open rate: 12.4%
- Delivery Rate: 99.96%

Two E-mails for Every Issue of *CAH&O*

e-TOC 1 – “Coming This Month” – delivered two weeks before the printed issue mails

- e-TOC links to hematologyandoncology.net
- Contents of current issue
- Highlights of past issues

e-TOC 2 – “In This Issue” – delivered days before the issue reaches the mailbox

- e-TOC links to hematologyandoncology.net
- Contents of current issue
- Highlights of future issues

Distribution

Primary Specialty	E-Mail Distribution
Gynecological Oncology (GO)	632
Hematology/Oncology (HO)	9,348
Medical Oncology (ON)	3,801
Musculoskeletal Oncology (OMO)	129
Pediatric Hematology/Oncology (PHO)	2,699
Surgical Oncology (SO)	435
Grand Total	17,044

Leaderboard (728 x 90)

Clinical Advances in
HEMATOLOGY & ONCOLOGY
A Peer-Reviewed Journal

[Website](#) | [Archives](#) | [Supplements](#) | [Videos](#) | [MMP Home](#)

July 2015

Coming in the July Issue of *CAH&O*

The Effect of Cancer Treatment on Cognitive Function
Asmita Kulkarni, MD, and Jamie S. Myers, PhD, RN, AOCNS

Immunotherapy or Molecularly Targeted Therapy: What is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?
Geoffrey T. Gloney, MD, and Michael B. Atkins, MD

July Columns

Second-Generation ALK Inhibitors
Hiroyuki Mano, MD, PhD

The Potential Threat to Blood Transfusion Safety of Emerging Infectious Disease Agents
Susan L. Stramer, PhD

Managing Primary Central Nervous System Lymphoma
Tatya Balachlor, MD, MPH

Stool DNA Testing: A New, Noninvasive Option for Colorectal Cancer Screening
David A. Ahlquist, MD

Highlights in Breast Cancer From the 2015 American Society of Clinical Oncology Annual Meeting
Commentary by Edith A. Perez, MD

Supplements to *CAH&O*

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Emerging Data on Multianalyte Algorithm Assays in Breast Cancer: A Clinical Review

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

New and Emerging Therapeutic Options for Thyroid Carcinoma

New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting

Managing Risk in Hodgkin Lymphoma

Wide skyscraper (160 x 600)

Medium rectangle (300 x 250)

Highlights From Past Issues

[Renal Cell Carcinoma in Patients With a Personal or Family History of Hematologic Malignancies](#)

[Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and Developing Novel Therapeutic Strategies](#)

[Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy](#)

[MET as a Drug Target](#)

[New Therapies for Polycythemia Vera](#)


[Imaging Techniques for Hepatocellular Carcinoma](#)

[The Future of Kidney Cancer Treatment](#)

[Intermittent Dosing in Melanoma](#)

[Hem/Onc News](#)

Video of the Week



TAS-102 vs placebo in patients 65 years with mCRC: An age-based analysis of the RECURSE trial

ASCO 2015 - Eric Van Cutsem, MD, PhD, discusses TAS-102 vs placebo in patients over 65 years with metastatic colorectal cancer - an age-based analysis of the RECURSE trial

Phase III RECURSE Trial

Abstract #3595 - TAS-102 vs placebo - an age-based analysis of the RECURSE trial

Abstract #3564 - TAS-102 vs placebo - Geographic Subgroups

Leaderboard (728 x 90)

Millennium Medical Publishing, Inc. | info@clinicaladvances.com | www.hematologyandoncology.net
 911 Broadway #310
 New York, NY 10012

If you no longer wish to receive notifications regarding the most current issue of *Clinical Advances in Hematology & Oncology*, please click here to unsubscribe. Replies to this message are not monitored or answered.

Copyright © 2015. All Rights Reserved

Millennium Medical Publishing, Inc. | 611 Broadway #310 | New York, NY 10012

In This Issue
 Cognitive Dysfunction
 Melanoma
 ALK Inhibitors
 Blood Transfusion
 CNS Lymphoma
 Colorectal Cancer
 Breast Cancer
 Immunotherapy

Stay Connected
 &

Forward To A Friend

Clinical Considerations in Patients With Myelofibrosis

Watch Now ▶



NICHOLAS J. SARRIS, MD, PhD



Online Advertising Rates & Closing Dates

CAH&O e-TOC Sponsorship

- Single sponsor = \$6,500 net
- Partial sponsor = \$4,500 net

Hematologyandoncology.net Advertising Rates

Limited sponsorship program, offered to just four annual sponsors at \$80,000 net per year. Each sponsor will receive approximately 200,000 total yearly impressions.

Digital Cancellations

In accordance with the AAAA/IAB Standard Terms and Conditions for Internet Advertising Version 3.0) found at http://www.iab.net/media/file/IAB_4Astsandcs-FINAL.pdf, Advertiser may cancel the I/O as follows:

For Flat-Fee or Fixed Placements:

- With minimum of 30 days prior written notice: no penalty
- With less than 30 days prior written notice: Advertiser is responsible for any contracted media to be served within 30 days

Send all digital material to Paul McDaniel at phm@clinicaladvances.com

CAH&O e-TOC Closing Dates*

Email Date	Insertion Order Due	Ad Material Due
1/8/2020	12/21/2019	1/3/2020
1/22/2020	1/8/2020	1/16/2020
2/5/2020	1/22/2020	1/27/2020
2/19/2020	2/5/2020	2/10/2020
3/5/2020	2/19/2020	2/24/2020
3/19/2020	3/5/2020	3/12/2020
4/9/2020	3/26/2020	4/2/2020
4/23/2020	4/9/2020	4/16/2020
5/7/2020	4/23/2020	4/30/2020
5/21/2020	5/7/2020	5/14/2020
6/4/2020	5/21/2020	5/28/2020
6/18/2020	6/4/2020	6/11/2020
7/9/2020	6/25/2020	7/2/2020
7/23/2020	7/9/2020	7/16/2020
8/6/2020	7/23/2020	7/30/2020
8/20/2020	8/6/2020	8/13/2020
9/10/2020	8/27/2020	9/4/2020
9/24/2020	9/10/2020	9/17/2020
10/9/2020	9/24/2020	10/2/2020
10/23/2020	10/8/2020	10/15/2020
11/5/2020	10/22/2020	10/29/2020
11/19/2020	11/16/2020	11/12/2020
12/3/2020	11/19/2020	11/28/2020
12/21/2020	12/10/2020	12/17/2020

*Dates are subject to change.

Digital Specifications

Specification	Website	e-TOC
Accepted ad sizes	Leaderboard (728 × 90)	Leaderboard (728 × 90)
	Medium rectangle (300 × 250)	Medium rectangle (300 × 250)
	Mobile leaderboard (320 × 50)	Wide Skyscraper (160 × 600)
Ad expansion available	Yes	N/A
Ad expansion sizes	Leaderboard (728 × 90)	N/A
Ad expansion notes	Ad must require user initiation before expansion. Expanded ad must include clearly visible close controls.	N/A
Ad formats	JPG, GIF, SWF, FLV files, HTML, rich media, Javascript, third-party served ads	JPG, GIF, animated GIF, third-party served ads
Maximum file size	40K	40K
Rich media file size	60K	N/A
Animation time	3 frames & 30 seconds, 3 loops	3 frames & 30 seconds, 3 loops*
Border	All ads with white or partially white background must use a 1-pixel black border	All ads with white or partially white background must use a 1-pixel black border
Third-party click and pixel tracking available?	Yes	Yes
Alternate text required	Yes	Yes
URL	Provide URL for any links	Provide URL for any links

For times when the user's browser does not support creative functionality (i.e. Flash™, HTML5), provide a standard image file.

*Outlook 2007 does not support animated GIFs and displays only a static image of the GIF. Please ensure that the first frame of the animated GIF makes sense as a static image.

Contact

Advertising: Paul McDaniel
 phm@clinicaladvances.com
 Direct (212) 995-5552 • Cell (917) 656-7994

Production: Vanessa Ray
 design@clinicaladvances.com • (212) 995-5568

Send all insertion orders to:
 phm@clinicaladvances.com

Clinical Advances in
HEMATOLOGY & ONCOLOGY™
A Peer-Reviewed Journal

Millennium Medical Publishing, Inc.
 611 Broadway, Suite 310, New York, NY 10012
 Tel: 212-995-5522
 Fax: 212-995-5572
 hematologyandoncology.net